CME Presentations

HER2+ Breast Cancer


Presentations


Speakers

  • Adam Brufsky, MD, PhD

    Adam Brufsky, MD, PhD

    Adam Brufsky, MD, PhD

    Adam M. Brufsky, MD, PhD, is professor of medicine and associate division chief for the Division of Hematology/Oncology at the University of Pittsburg School of Medicine in Pennsylvania. He serves as co-director of the Comprehensive Breast Cancer Center and medical director of the Women’s Cancer Center at the UPMC Magee-Women’s Hospital. Dr Brufsky is the principal investigator on a number of research grants funded by the National institute of Health and the Susan G. Komen Foundation. He has authored or co-authored numerous abstracts and research articles in prominent journals, including the New England Journal of Medicine. Dr Brufsky is an active member of the American Society of Clinical Oncology and the American Association for Cancer Research.
  • Ann Partridge, MD, MPH

    Ann Partridge, MD, MPH

    Ann Partridge, MD, MPH

    Ann Partridge, MD, MPH, is professor of medicine at Harvard Medical School and vice chair of Medical Oncology at Dana-Farber Cancer Institute in Boston, where she also serves as director of the Adult Survivorship Program and leads the Program for Young Women with Breast Cancer. Her most substantial research contributions focus on the clinical epidemiology of breast cancer in young women, aiming to understand and improve their care and outcomes. Dr Partridge serves in leadership roles nationally and internationally, including as co-chair of the Breast Committee of the Alliance for Clinical Trials in Oncology. She has received prior awards, including a Champions of Change award from the White House. Dr Partridge received her medical degree from Cornell University Medical College in New York.

CME Information

Metastatic HER2-Positive Disease: Overcoming HER2 Resistance


PIM LogoPQH Logo

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

  • Evaluate therapeutic options for the HER2 blockade in the first-line setting for HER-positive metastatic breast cancer (MBC)
  • Compare and contrast safety and efficacy data of the second-line and beyond for HER2-positive MBC
  • Evaluate how novel HER2-targeted treatment options with improved safety profiles can be incorporated as second-line and beyond options in the management of MBC
  • Assess the therapeutic implications of ongoing clinical trials involving emerging agents for advanced HER2-positive disease
Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC.

ACKNOWLEDGEMENT

This activity is supported by an educational grant from Daiichi Sankyo, Inc., Seattle Genetics, Inc., and an independent educational grant from AstraZeneca.

TUITION

Complimentary

JointlyAccreditedProvider Logo

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION STATEMENTS

Physician Continuing Medical Education

Live Activity

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Enduring Material

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

Live Activity
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Enduring Activity
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

DATE OF RELEASE/EXPIRATION

Live Activity

June 23, 2020 from 12:00 PM EST – 1:00 PM EST.

Enduring Material

The enduring material will be available from June 23, 2020 – June 23, 2021.

TARGET AUDIENCE

This activity is intended for medical oncologists, surgeons, pathologists, oncology nurses, physician assistants, oncology pharmacists, and other clinicians involved in the management of patients with HER2+ breast cancer.

ESTIMATED TIME TO COMPLETE

This activity consists of one session which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To participate in the activity, go to www.OMedLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test..

HARDWARE / SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Ann Partridge, MD N/A
Adam Brufsky, MD, PhD Consulting Fee: AstraZeneca, Roche, Puma, Seattle Genetics

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Tariqa Ackbarali
Senior Medical Director, Patient Education
PlatformQ Health Education, LLC
None

The PIM planners and managers have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Alissa Stone, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:
Please contact the Postgraduate Institute for Medicine at www.pimed.com.

Technical Support:
For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.